Braingaze, a digital health company developing solutions to detect, diagnose, and treat cognitive disorders such as ADHD and Alzheimer's disease, has secured $1.6M in seed funding.
The startup's technology leverages patented "eye movement cognitive vergence," analyzing small, involuntary eye movements as a unique marker and enabler of cognitive processing. Braingaze's digital health tools have already been utilized for years in leading clinics, backed by an international team of scientists and product developers.


















